StIR Compositions for Lung Infection Resistance via TLR Agonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional methods and compositions to effectively inhibit and treat microbial infections, particularly in the lungs where the structural vulnerability makes it challenging to defend against pathogens.
Innovation Solution
The development of compositions that stimulate innate resistance (StIR) in the lungs, specifically using one or more ligands for innate receptors such as Toll-like receptor (TLR) agonists, to enhance the body's natural defenses against microbial infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If the lungs maintain a large surface area for gas exchange, then ventilation efficiency is improved, but susceptibility to infection increases due to minimal barrier defense
Solution Approach 1:
The patent applies preliminary action by administering TLR agonists before pathogen exposure to pre-stimulate innate immune receptors in the lungs. This priming of the immune system enhances the lung's ability to detect and respond to pathogens, thereby reducing susceptibility to infection while maintaining the large surface area needed for ventilation.
Solution Approach 2:
The patent uses TLR agonists as intermediary substances that bridge the gap between the vulnerable lung surface and the immune defense system. These agonists activate pattern recognition receptors on airway epithelial cells and immune cells, triggering a protective immune response without directly blocking pathogen entry, thus preserving ventilation while enhancing infection resistance.
2Reliability
If the lungs use mechanical and cellular mechanisms for defense, then infection resistance is improved, but response time is delayed compared to direct antimicrobial action
Solution Approach 1:
The patent applies preliminary action by pre-stimulating TLRs with agonists before pathogen challenge. This activates signaling pathways and induces expression of antimicrobial peptides and inflammatory cytokines in advance, so that when pathogens arrive, the immune response is already partially primed and can act more rapidly, reducing the delay inherent in conventional mechanical and cellular defense mechanisms.
3Productivity
If the lungs expose 100 m2 surface area to the external environment, then gas exchange capability is improved, but the barrier defense is minimized making the lungs vulnerable to pathogens
Solution Approach 1:
The patent introduces TLR agonists as intermediary substances that enable the lung's large surface area to maintain both gas exchange function and pathogen detection capability. The agonists activate pattern recognition receptors distributed across the airway epithelium, creating a surveillance system that operates alongside the gas exchange function, allowing the lungs to remain open to the environment while being alert to pathogens.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The StIR compositions provide a rapid and temporal enhancement of biological defenses in the lungs, effectively attenuating microbial infections by inhibiting, treating, or preventing infection or microbial growth or survival.
Implementation Method 1
The StIR composition comprises one or more ligands for one or more innate receptors. A number of innate receptors have been identified as including, but not limited to, Toll-like receptor (TLR), C-type lectin receptors (CLRs), and nucleotide-binding oligomerization domain-like receptors (Nod-like receptors or NLRs).
Implementation Method 2
Once these microbes are present on or in the skin or intestinal tract, lung, and genitorurinary mucosa, they are recognized by TLRs, which activates immune cell responses.
Implementation Method 3
In response to viral, fungal, or allergic inflammation, airway secretory cells rapidly increase their height and fill their apical cytoplasm with secretory granules, a process termed inflammatory metaplasia
Implementation Method 4
Alveolar macrophages that reside in the most distal airspaces are able to ingest these organisms, thereby clearing the lungs from a potential infection.
Implementation Method 5
the constitutive presence of antimicrobial peptides in the airway lining fluid limits their growth
Implementation Method 6
Most inhaled microbial pathogens fail to penetrate to the alveoli due to impaction against the airway walls, where they are entrapped by mucus and then expelled via the mucociliary escalator system
Implementation Method 7
microbial interactions with respiratory epithelial pattern recognition receivers causes numerous microbicidal products to be expressed into the airway lining fluid, including defensins, cathelicidins, lysozyme, and reactive oxygen species
Data Source
AI summary
Embodiments of the invention are directed to methods of treating, inhibiting or attenuating a microbial infection in an individual who has or is at risk for developing such an infection, comprising the step of administering an effective amount of a StIR composition to the individual.